SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst heightened competitive concerns following Amazon Pharmacy's direct offering of Novo Nordisk's GLP-1 weight loss pill, which many in the community view as a significant headwind. While a vocal bearish contingent cites overvaluation and predicts further downside, a segment of investors sees current price levels as a strong buying opportunity, banking on the company's diversified telehealth platform and international expansion. The market is actively debating HIMS's growth trajectory and valuation as it navigates this evolving competitive landscape.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is seeing a surge in attention following positive FDA feedback, which significantly de-risks its lead asset sonelokimab by clarifying a direct regulatory pathway without additional trials. This catalyst, combined with notable insider buying and multiple analyst upgrades, is driving strong community sentiment and fueling speculation for an imminent buyout or substantial re-rating in the competitive immunology market.

NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.

Novabay Pharmaceuticals Inc

Novabay Pharmaceuticals (NBY) is experiencing extreme volatility and massive gains, largely fueled by a significant special cash dividend and discussions around a potential pivot to blockchain-based assets. The community is intensely focused on short squeeze potential and the dividend's impact, though many debate the company's underlying fundamentals against the backdrop of its dramatic price movements.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending with investors expressing a mix of frustration over recent stock performance and renewed optimism for Briumvi's competitive standing. The community is actively discussing a competitor's recent regulatory setback, which highlights Briumvi's favorable profile, while anticipating potential strategic updates from the upcoming J.P. Morgan Healthcare Conference.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as escalating U.S. actions in Venezuela, including military operations and blockades, create market uncertainty. Investors are sharply divided: some anticipate a significant oil price surge due to supply disruptions, while others predict eventual price stabilization or declines if new Venezuelan supply comes online and global oversupply persists. The financial community is closely watching the geopolitical implications of this evolving situation.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is trending as unseasonably warm weather continues to dampen heating demand, driving natural gas prices to multi-week lows. This sharp decline has fueled widespread frustration and significant losses among long holders, who are fiercely debating whether a bottom is in or if an anticipated "polar vortex" can ignite a major rebound against the ETF's inherent decay.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings Limited is experiencing intense trading activity following news of a significant private placement and an acquisition, coinciding with the expiration of its IPO lock-up period. This low-float international stock is generating widespread community discussion, with many anticipating a substantial short squeeze and comparing its trajectory to other highly volatile market movers. However, considerable caution is also being voiced, highlighting the speculative nature and potential for rapid price movements.

Stafi is the first DeFi protocol unlocking liquidity of staked assets. Users can stake PoS tokens through Stafi and receive rTokens in return, which are available for trading while still earning staking rewards. FIS is the native token on Stafi Chain. FIS is required to provide security to the network by staking, pay for transaction fees on the Stafi chain, mint &amp; redeem rTokens.

StaFi

StaFi (FIS) is currently trending with significant community discussion around its recently announced token burn proposal, aiming for deflationary tokenomics, and a new roadmap. Despite a recent delisting, strong bullish sentiment persists due to its perceived low market cap and continued presence on major exchanges, with many anticipating substantial upside as a liquid staking protocol.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is currently trending due to a significant agreement with Meta Platforms to develop a nuclear energy campus in Ohio, aimed at powering future AI data centers. This deal, alongside anticipated DOE support for fuel and recent discussions on nuclear energy, has fueled intense bullish sentiment regarding the future of small modular reactors for AI infrastructure, despite some community concerns over current revenue and regulatory timelines.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund (XLE) is a major talking point as geopolitical shifts in Venezuela, including reports of US influence over its oil sector, ignite discussions about potential supply changes. This development is fueling community debate, with many anticipating a significant energy sector breakout and capital rotation, while others remain cautious about long-term infrastructure challenges and potential oversupply impacts on oil prices.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA BioMarin to Present at the 44th Annual J.P. Morgan...

Veeva and BioMarin Form Long-Term Strategic Partnership

Veeva and BioMarin Form Long-Term Strategic Partnership Veeva and BioMarin Form Long-Term Strategic Partnership PR Newswire PLEASANTON, Calif., and SAN RAFAEL, Calif., Jan. 8, 2026 Partnership to...

19,329 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Financiere des Professionnels Fonds d investissement inc.

Financiere des Professionnels Fonds d investissement inc. bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) during the 3rd quarter, according to the company in...

Blue Trust Inc. Sells 17,973 Shares of BioMarin Pharmaceutical Inc. $BMRN

Blue Trust Inc. decreased its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 94.5% in the third quarter, according to the company in its most recent 13F filing with the...

VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in BioMarin Pharmaceutical Inc. $BMRN

VIRGINIA RETIREMENT SYSTEMS ET Al cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 37.3% in the third quarter, according to its most recent Form 13F filing with the...

Cwm LLC Has $8.90 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN

Cwm LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 86.9% in the third quarter, according to its most recent Form 13F filing with the Securities and...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives Consensus Rating of "Moderate Buy" from Analysts

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has been given an average rating of "Moderate Buy" by the twenty-five research firms that are covering the company, MarketBeat.com...

Rice Hall James & Associates LLC Boosts Stock Position in BioMarin Pharmaceutical Inc. $BMRN

Rice Hall James & Associates LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 1,693.1% in the 3rd quarter, according to the company in its most recent...

BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 10,580.1% during the third quarter, according to the company in its most recent Form 13F filing...

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Amicus Therapeutics, Inc. (NasdaqGM: FOLD) to...

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Current Price	$58.95
Prev Close	$60.35
Open	$60.52
Dividend Yield	0.00%
50-Day Moving Average	$55.22
Beta	0.72
Avg. Volume	2.93M
PE Ratio	22.61

52-Week High	$73.51
52-Week Low	$50.76
Market Capitalization	$11.59B
EPS (Annual)	$2.21
Price to Book	1.91
Revenue Per Employee	$933,949.67
Enterprise Value/EBITDA	N/A

BMRN
Biomarin Pharmaceutical Inc. - Registered Shares

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BMRN News

BMRNBiomarin Pharmaceutical Inc. - Registered Shares